Image: happy man and woman

ABOUT US

Contact us

ANTIPLATELET THERAPY

Educational Films

We Need your help Image: Two people emailing

Have you had a deep vein thrombosis (blood clot in the legs) or a pulmonary embolism (blood clot on the lungs) either while you were in hospital or shortly after being discharged? Or has this happened to a relative of yours?

Over 25,000 people die every year following a DVT or PE after a stay in hospital.

AntiCoagulation Europe is producing an educational programme to highlight the risks of DVT and PE and needs to talk to people who have had this experience, or to relatives of those who have died.

Please help us to help others. Email your story in the first instance to anticoagulation@ntlworld.com



 

Welcome to the Anticoagulation Europe web site


We hope you will find it interesting and useful.

We always welcome feedback and value your opinions, so please let us know if you have any comments or suggestions about the site.

You will find out a little more about who we are at About Us.


AntiCoagulation Europe is collaborating with Roche Diagnostics Ltd to coordinate the CoaguNation Bus Tour

For more information see events page.


First oral anticoagulant to be licensed in over 50 years

· A daily pill that could help prevent deaths from blood clots following elective hip and knee replacement surgery has received its license

· Bloods clots or venous thrombo-embolism (VTE), cause 1 in 10 fatalities in hospital and kill at least 25,000 people in the England every year - more than 20 times the number of deaths attributed to the superbug MRSA

· The pill, called Pradaxa® (dabigatran etexilate), is the first new blood-thinning treatment to be made available as a tablet in over half a century

· Currently, many patients undergoing hip and knee replacement surgery who should receive medicines to prevent blood clots are not doing so

Many of the 130,000 UK patients who every year undergo total hip or total knee replacement are at high risk of developing a venous thrombo-embolism or VTE. VTE may occur inside a deep vein, partially or totally blocking the flow of blood - this is called a deep vein thrombosis or DVT. Without treatment to prevent VTE as many as 60 per cent of patients will develop a DVT, while up to 1 in 10 patients will develop a potentially fatal pulmonary embolism (PE), where the clot breaks loose and travels to the lungs.

Want to self test?

Having trouble getting your test strips available on prescription?

There is an ACE resource pack designed to help you - see Campaigns

 

Hospital-acquired DVT Guidance

In a move to reduce the 25,000 deaths a year from hospital-acquired deep vein thrombosis and pulmonary embolism, the Chief Medical officer issues his guidance on Hospital Acquired Venous Thromboembolism (deep vein thrombosis and pulmonary embolism) - see News and Developments

The National Institute for Clinical Excellence (NICE) has now issued its guidance for surgical patients - see News and Developments

 

LATEST UPDATE on Prescription Campaign CLICK HERE


 

The views and opinions expressed in the personal experiences listed on this web site are not necessarily those of AntiCoagulation Europe.

No item may be reproduced without the permission of AntiCoagulation Europe.

anticoagulation@ntlworld.com

Copyright AntiCoagulation Europe 2006
Registered Charity No 1090250

Text too small? Click here.

AntiCoagulation Europe, PO Box 405, Bromley, Kent BR2 9WP | Tel: 020 8289 6875


PLEASE NOTE THIS WEBSITE SHOULD NOT BE USED TO REPLACE ADVICE FROM YOUR DOCTOR


We welcome feedback about our website. Please email your comments to
anticoagulation@ntlworld.com

 

Contact us by email

 

Contact us by post, phone or fax

 

What is atrial fibrillation?

 

About Cardioversion

 

ABout Ablation

 

Lionel

 

TIPS TO HELP YOU AVOID A DVT

 

TRAVELLER'S THROMBOSIS

 

Stress and heart disease

 

Medical Alert identity Card

 

MARIANNE GILL

 

John Kelman

 

MICHAEL KNIGHT

 

Evelyn Richardson

 

Max Crompton

 

1. Introduction

 

2. Overview

 

3. How to Roll out a near-patient testing service in Primary care

 

4. The importance of quality control and assurance and Selecting a POC device

 

5. Rolling out a Patient self-testing service

 

6. The patient's perspective

 

7. A personal account

 

8. Conclusion

 

Breaking News

 

European Medicines agency recommends approval of Dabigatran etexilate

 

UNipath withdraws smartchek

 

A guide to setting up Near Patient Testing in Primary Care

 

NICE guidelines for atrial fibrillation

 

Near patient Testing in Tayside

 

Patients capable of self-testing: a systematic review

 

Breaking News

 

European Medicines agency recommends approval of Dabigatran etexilate

 

UNipath withdraws smartchek

 

NICE guidance on Venous Thromboembolism (VTE)

 

Venous thromboembolism CMO press release

 

Front Line in Stroke Prevention - Report

 

New hope for early detection of deep vein thrombosis

 

NICE guidelines for atrial fibrillation

 

Ongoing trials for new oral anticoagulant

 

Expert pharmacists get the go-ahead

 

Patients capable of self-testing: a systematic review

 

News archive

 

'Strips on prescription' resource pack

 

Abolition of prescription charges

 

Equality for the Republic of Ireland

 

It's about time

 

It's about time survey

 

conference for health care professionals: Improving patient Safety and Managing Risks Associated with Anticoagulation Therapy

 

Conference 2008

 

Flora London MArathon 2008

 

CoaguNation Bus Tour

 

Roche Diagnostics launches CoaguNation Club

 

INR Test Monitors

 

Breaking news